Search: onr:"swepub:oai:DiVA.org:liu-33253" >
Outcomes of reduced...
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia : an analysis of prognóstic factors from the Chronic Leukemia Working Party of the EBMT
-
Crawley, C (author)
-
Szydlo, R (author)
-
Lalancette, M (author)
-
show more...
-
Bacigalupo, A (author)
-
Lange, A (author)
-
Brune, M (author)
-
- Juliusson, Gunnar, 1954- (author)
- Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine
-
Nagler, A (author)
-
Gratwohl, A (author)
-
Passweg, J (author)
-
Komarnicki, M (author)
-
Vitek, A (author)
-
Mayer, J (author)
-
Zander, A (author)
-
Sierra, J (author)
-
Rimbaldi, A (author)
-
- Ringden, O (author)
- Karolinska Institutet
-
Niederwieser, D (author)
-
Apperley, JF (author)
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2005
- 2005
- English.
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 106:9, s. 2969-2976
- Related links:
-
http://bloodjournal.... (free)
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- This study reports outcomes of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning (RIC) in 186 patients with chronic myeloid leukemia (CML) from the European Group for Blood and Marrow Transplantation (EBMT). The median age was 50 years, and 64% were in first chronic phase (CP1), CP2 13%, accelerated phase 17%, and blast crises 6%. The median EBMT transplant score was 3. The day 100 transplantation-related mortality (TRM) was 6.1% (confidence interval [CI], 3.4%-11%) but rose to 23.3% (CI, 14%-27%) at 2 years. Fludarabine, busulfan, and antithymocyte globulin (Fd/Bu/ATG) was associated with the lowest TRM of 11.6% (CI, 4.7%-11%) at 1 year. Acute graft-versus-host disease (GvHD) grade II to IV occurred in 32% and chronic GvHD in 43% (extensive in 24%). ATG was associated with a lower incidence of chronic GvHD (cGvHD). The overall survival (OS) and progression-free survival (PFS) at 3 years were 58% (CI, 50%-66%) and 37% (CI, 30%-45%), respectively. Adverse OS was associated with advanced disease (relative risk [RR], 3.4). PFS was inferior in advanced disease (RR, 2.7) and a trend to improved outcomes with Fd/Bu/ATG (RR, 0.58). RIC allografts are feasible in CML in first or second CP. Since no other RIC regimen demonstrated superiority, Fd/Bu/ATG should be considered as baseline in future prospective trials.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Crawley, C
-
Szydlo, R
-
Lalancette, M
-
Bacigalupo, A
-
Lange, A
-
Brune, M
-
show more...
-
Juliusson, Gunna ...
-
Nagler, A
-
Gratwohl, A
-
Passweg, J
-
Komarnicki, M
-
Vitek, A
-
Mayer, J
-
Zander, A
-
Sierra, J
-
Rimbaldi, A
-
Ringden, O
-
Niederwieser, D
-
Apperley, JF
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood
- By the university
-
Linköping University
-
Lund University
-
Karolinska Institutet